fbpx

HIV Antiretrolviral Medication Antitrust Settlement

Settlement Structure: Claims Made

Active: Open

Case Summary:

A partial settlement has been reached in an antitrust class action alleging that certain drug companies violated antitrust and consumer protection laws in certain states by engaging in anticompetitive conduct. The complaint alleged that the anticompetitive conduct caused consumers and third-party payors to pay too much for the HIV medicines Atripla, Biktarvy, Complera, Descovy, Evotazz, Odefsey, Prezcobix, Stribild, Symtuza, Truvada, and Viread.

The defendants settling at this time are Bristol-Myers Squibb Company and ER Squibb & Sons, LLC. The case is proceeding against Gilead Sciences, Inc. Gilead Holdings, LLC, Gilead Sciences, LLC, Gilead Sciences Ireland US, Janssen Products LP, and Janssen R&D Ireland.

Docket Number:

3:19-cv-02573-EMC

Company: Bristol-Myers Squibb

Filing Deadline: January 1, 2100

Class Period: May 14, 2015 to October 13, 2021

Objection Deadline: March 15, 2022

Exclusion Deadline: March 15, 2022

Final Approval Hearing: April 28, 2022

Proof of Purchase:

The claim form does not ask for documentation at this time but class members may be asked for it in the future.

Eligibility:

You may be eligible if you are a member of one of the following classes:

- Atripla Settlement Damages Class (individual payors and TPPs)
- Evotaz Settlement Damages Class (individual payors and TPPs)
- Complera Settlement Damages Class (only TPPs)
- Stribild Settlement Damages Class (only TPPs)
- Truvada Settlement Damages Class (only TPPs)
- cART Foundation Settlement Injunctive-Relief Class (no money damages)
- Prezcobix Settlement Injunctive-Relief Class (no money damages)

No money damages will be paid in the injunctive-relief settlements. The damages states are Alabama, Arizona, Arkansas, California, Connecticut, District of Columbia, Florida, Hawaii, Idaho, Illinois, Iowa, Kansas, Maryland, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon, Rhode Island, South Dakota, Tennessee, Utah, Vermont, West Virginia, and Wisconsin.
For details of the various classes and class periods, see the Notice at https://www.hivdrugsettlement.com/documents/Staley%20LF%20FINAL.pdf.

The deadline for filing claims is sixty days after final approval of the settlement.

Typical Settlement Amount:

Unknown at this time. The money from this partial settlement will be distributed according to a plan of allocation, with some going to litigation costs, some going to noticing costs, some going to individual class members, and some retained for TPP class members. A Plan of Allocation has been filed with the court.

Total Settlement Amount: $10,000,000 so far, plus half the costs of settlement noticing

Class Representative Proposed Incentive Fee:

Unknown at this time

Law Firms:
Durie Tangri, LLP
Hagens Berman
Hilliard & Shadowen LLP

Claim Form: HIV Antiretrolviral Medication Antitrust Settlement Claim Form

Case Name: Staley, et al. v. Gilead Sciences, Inc., et al.

Settlement Website: HIV Antiretrolviral Medication Antitrust Settlement Website

Claims Administrator:
AB Data, Ltd.

Claims Administrator Contact Information:

Staley, et al. v. Gilead Sciences, Inc., et al.
P.O. Box 173017
Milwaukee, WI 53217
info@HIVDrugSettlement.com
877-999-2491

Tags: Antitrust, Collusion and Price Fixing